Search Results 501-510 of 11393 for anti-TNF drugs

1. Efficacy And Safety Of Tislelizumab In Combination With Fruquintinib In Participants With Selected Solid Tumors - Mayo Clinic

   ... treatment with anti-tuberculosis therapy within 1 year before the first drug administration. History or presence of interstitial lung disease, noninfectious ...

2. Carboplatin And Paclitaxel With Or Without Atezolizumab Before Surgery In Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer - Mayo Clinic

   Drugs used in chemotherapy ... TNF] agents) within 2 weeks prior to cycle 1, day 1: ... A stable regimen of highly active anti-retroviral therapy (HAART); ...

3. Study Of Targeted Therapy Vs. Chemotherapy In Patients With Thyroid Cancer - Mayo Clinic

   The purpose of this study is to compare progression-free survival (PFS) in patients with BRAF V600Em differentiated thyroid cancer who progressed on frontline ...

4. Alpha-1-antitrypsin deficiency - Diagnosis and treatment - Mayo Clinic

   AATD-specific treatment replaces missing AAT protein through infusions. Standard COPD therapy includes medicines, oxygen therapy and pulmonary rehabilitation.

5. Atezolizumab In Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer - Mayo Clinic

   ... TNF] agents) within 4 weeks prior to cycle 1, day ... drugs); replacement therapy ... A stable regimen of highly active anti-retroviral therapy (HAART) ...

6. Trabectedin (intravenous route) - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

7. Tocilizumab-bavi (intravenous route) - Side effects & uses - Mayo Clinic

   Tocilizumab-bavi injection is used alone or together with other medicines to treat moderate to severe active rheumatoid arthritis in patients who have been ...

8. Lymphoma Clinical Trials

   Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed ...

9. BT – L-CsA – 301 – SLT: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial To Demonstrate The Efficacy And Safety Of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via The PARI Investigational EFlow® Device Plus Standard Of Care Versus Standard Of Care Alone In The Treatment Of Chronic Lung Allograft Syndrome / Bronchiolitis Obliterans Syndrome In Patients Post Single Lung Transplantation - Mayo Clinic

   About this study. The purpose of this study is to analyze L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with Bronchiolitis ...

10. A Study To Evaluate The Safety And Effectiveness Of Ustekinumab As Initial Or Maintenance Therapy For Patients With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    Drugs & Supplements A-Z · Health ... Is naïve to biologic therapy (TNF antagonists or vedolizumab) ... anti-tumor necrosis factors (TNFs) for at least 8 weeks.